JAZZJazz Pharmaceuticals plc

$11B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$601M+11.8% YoY

Gross Profit

$559M93.0% margin

Operating Income

$196M32.7% margin

Net Income

$148M24.7% margin

EPS (Diluted)

$2.64

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

$258M

Free Cash Flow

$255M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$6.3B

Total Liabilities

$2.9B

Stockholders' Equity

$3.4B

Cash & Equivalents

$742M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$601M	$538M	+11.8%
Gross Profit	$559M	$506M	+10.4%
Operating Income	$196M	$133M	+47.4%
Net Income	$148M	$102M	+44.9%

Revenue Segments

Product And Services, Product Sales Net Of Deductions

$597M50%

Xyrem

$448M37%

Defitelio/Defibrotide

$50M4%

Zepzelca

$37M3%

Vyxeos

$31M3%

Erwinaze And Erwinase

$20M2%

Sunosi

$9M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Other Products

$2M0%

Geographic Segments

UNITED STATES

$548M91%

Europe

$46M8%

Other Countries

$7M1%